The time for regionalised vaccine manufacturing has arrived

Many countries want more self-sufficiency in vaccine manufacturing, given the lessons of the COVID-19 pandemic when there were considerable delays in accessing COVID-19 vaccines due to supply constraints and export bans. 3 With increasingly constrained donor funds for health, global procurement mechanisms must prioritise the most efficient allocation of financial resources to meet global demand, meaning some local health needs are unable to be met. 4 Regions, too, want their own solutions to mobilise greater investment in health to fill these gaps. [...]sustainable vaccine markets need predictable demand. 12 Pooling demand on a regional basis is a good first step towards defining a regional market for vaccines. GC has consulted for the Bill & Melinda Gates Foundation, Gates MRI, and PATH; is an Operating Partner at Adjuvant Capital, a commercial life sciences investment fund; is an independent unpaid Board Member of the biotechnology commercial company Codagenix, in which Adjuvant Capital is an investor; is an Application Reviewer for the RIGHT Foundation; and holds vaccine company stocks (as exchange-traded funds) in retirement assets.